Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease-Reference-Cited by-同舟云学术

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease

Published:2020-01-17 Issue:4 Volume:17 Page:242-257
ISSN:1759-5002
Container-title:Nature Reviews Cardiology
language:en
Short-container-title:Nat Rev Cardiol

Author:

Capodanno Davide,Bhatt Deepak L.^ORCID,Eikelboom John W.,Fox Keith A. A.^ORCID,Geisler Tobias,Michael Gibson C.^ORCID,Gonzalez-Juanatey Jose Ramon,James Stefan,Lopes Renato D.,Mehran Roxana,Montalescot Gilles,Patel Manesh,Steg P. Gabriel,Storey Robert F.,Vranckx Pascal,Weitz Jeffrey I.,Welsh Robert,Zeymer Uwe,Angiolillo Dominick J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://www.nature.com/articles/s41569-019-0314-y.pdf

Reference101 articles.

1. Antithrombotic Trialists’ (ATT) Collaboration et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).

2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348, 1329–1339 (1996).

3. Bhatt, D. L. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706–1717 (2006).

4. Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791–1800 (2015).

5. Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012).

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention;Interventional Cardiology Clinics;2024-10

2. Engineered P2Y₁₂-Overexpressing Cell-Membrane-Wrapped Nanoparticles for the Functional Reversal of Ticagrelor and Clopidogrel;Nano Letters;2024-08-14

3. The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic stroke;Expert Opinion on Pharmacotherapy;2024-07-02

4. Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation;Expert Review of Cardiovascular Therapy;2024-07

5. CLINICAL PERFORMANCE AND PERSISTENCE ON DUAL PATHWAY INHIBITION WITH RIVAROXABAN AND ASPIRIN IN REAL-WORLD SETTING.;Journal of Cardiovascular Pharmacology;2024-05-20